McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Can MCK overcome its sustaining challenges with robust finances and innovation?

S&P Global Ratings has revised its outlook on McKesson Corp (NYSE:MCK). to positive from stable, while affirming its 'BBB+' ...

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on McKesson (MCK – Research Report), with a ...

Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors ...

In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on McKesson (MCK – Research Report). The ...

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its ...

With a positive outlook, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55 to $32.95, indicating ...

McKesson Corporation MCK recently announced that it has signed a definitive agreement to acquire a controlling interest in ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines. The Conshohocken, Pennsylvania-based company now expects its ...

Healthcare Distribution Market Set To Witness Significant Growth By 2025-2032: Consorta, Inc., Cardinal Health, Inc Healthcare Distribution Market is estimated to be valued at USD 1,050.2 Bn in 2024 ...

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail ...